In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCl

Six preparations were considered: three multiple unit dosage forms (micropellets in capsules) (D, E and G) and one matrix tablet (B) were experimental prolonged release formulations, two non‐disintegrating tablets (A and C) were commercial products. The in vitro dissolution behaviour of the differing formulations was investigated using the USP XXII paddle apparatus.

[1]  M. Masana,et al.  Bioequivalence of two pharmaceutical forms of diltiazem. , 1990, Biopharmaceutics & drug disposition.

[2]  W. Westlake,et al.  Symmetrical confidence intervals for bioequivalence trials. , 1976, Biometrics.

[3]  R. N. Brogden,et al.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy. , 1985, Drugs.

[4]  J. Lacz,et al.  Quantitation of diltiazem and desacetyldiltiazem in dog plasma by high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.

[5]  Gerhard Levy,et al.  Development of In Vitro Dissolution Tests which Correlate Quantitatively with Dissolution Rate-Limited Drug Absorption in Man , 1965 .

[6]  R. Gomeni,et al.  Pharmacokinetics and metabolism of diltiazem in man. , 1980, Acta cardiologica.

[7]  P. du Souich,et al.  Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. , 1990, Biopharmaceutics & drug disposition.

[8]  J. Wagner,et al.  Per cent absorbed time plots derived from blood level and/or urinary excretion data. , 1963, Journal of pharmaceutical sciences.

[9]  P. Höglund,et al.  Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. , 1989, Therapeutic drug monitoring.

[10]  E. U. Kölle,et al.  High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. Application to pharmacokinetics. , 1985, Journal of chromatography.

[11]  P. Höglund,et al.  No Effect of Terodiline on Anticoagulation Effect of Warfarin and Steady‐State Plasma Levels of Warfarin Enantiomers in Healthy Volunteers , 1989, Therapeutic drug monitoring.

[12]  E. Kinney,et al.  The pharmacokinetics of diltiazem in healthy American men. , 1982, The American journal of cardiology.

[13]  G. Bianchetti,et al.  Bioavailability of diltiazem as a function of the administered dose , 1991, Biopharmaceutics & drug disposition.

[14]  P. Höglund,et al.  Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. , 1989, Therapeutic drug monitoring.